iShares Nasdaq Biotechnology ETF (IBB)

104.20
Delayed Data
As of May 24
 +0.43 / +0.41%
Today’s Change
89.01
Today|||52-Week Range
122.97
+8.06%
Year-to-Date

Investment Objective

The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Advisory Services Network, LLC Buys iShares Core U.S. ...
May 20 / GuruFocus NewsGURU - Paid Partner Content
 

Performance

1 month-1.27% 3 years+4.97%
3 months-5.91% 5 years+6.10%
1 year-2.70% Since inception+6.59%
Data through 05/25/2019

Quote Details

Previous close$103.77
Open day’s range103.83 – 105.17
Net asset value (NAV)104.24 (05/24/2019)
Daily volume1,342,149
Average volume (3 months)2,486,501
Data as of 4:00pm ET, 05/24/2019

Peer Comparisonvs. Health ETFs

 IBBCategory
Performance 5-yr return+6.10%+10.02%
Expense Gross exp ratio0.47%1.26%
Risk 5 year sharpe ratio0.370.60
Net assets$7.7B$3.0B
Average market cap$13.8B$34.4B
Average P/E17.324.9
Dividend / Share--0.26%

Competitors

FHLC Fidelity® MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...
IHI iShares U.S. Medical Devices ETF

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 99.91%
Business service 0.09%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
CELG Celgene8.54%
GILD Gilead Sciences8.46%
AMGN Amgen7.98%
BIIB Biogen5.79%
VRTX Vertex Pharmaceuticals Inc5.55%
ILMN Illumina Inc4.22%
ALXN Alexion Pharmaceuticals Inc4.15%
REGN Regeneron Pharmaceuticals3.37%
INCY Incyte Corp2.24%
BMRN Biomarin Pharmaceutical Inc2.08%